Literature DB >> 12581955

[Tumor necrosis factor-alpha pretreatment for in vitro culture of mature dendritic cells].

Chun-hua Pan1, Rong-cheng Luo.   

Abstract

OBJECTIVE: To explore a new method for in vitro culture of mature dendritic cells (DCs) by utilizing the maturation-inducing effect of tumor necrosis factor-alpha(TNF-alpha) on DC precursors.
METHODS: Freshly isolated DC precursors (peripheral blood-derived monocytes) were initially cultivated for 4 h in RPMI 1640 supplemented with 10% fetal bovine serum and containing TNF-alpha (200 U/ml), followed by treatment with rhGM-CSF (800 U/ml) and interleukin (IL)-4 (500 U/ml) added into the medium. After 48 and 96 h, the 3 cytokines were simultaneously added to the medium for further culture. On day 8 of cell culture, the DCs were harvested and designated as T-DCs, which were subsequently subjected to examinations of flow cytometry analysis, assay by autologous and allogeneic mixed lymphocyte reaction (MLR) for estimating their maturation, and MTT assay for their specific killing activity.
RESULTS: The T-DCs expressed specific surface markers (CD83,CD1a, CD54, CD11a, CD80, CD86, HLA-DR, CD83HLA-DR) of mature DCs, and stimulated strong T-cell proliferative responses in both autologous and autogeneic MLR. It also activated CD4+ T cells, which proliferated in response to autologous tumor, and specifically lysed tumor targets.
CONCLUSION: The DCs thus cultured in vitro possess typical phenotype, and can present antigens to T cells, and this method provides an alternative in culturing mature and functionally competent DCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12581955

Source DB:  PubMed          Journal:  Di Yi Jun Yi Da Xue Xue Bao        ISSN: 1000-2588


  1 in total

1.  Dioscin attenuates oxLDL uptake and the inflammatory reaction of dendritic cells under high glucose conditions by blocking p38 MAPK.

Authors:  Ying Li; Yong Li; Te Yang; Ming Wang
Journal:  Mol Med Rep       Date:  2019-11-06       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.